Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anlotinib + benmelstobart + HAIC
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intra-arterial, Intravenous, Oral
01
Overview
Anlotinib + benmelstobart + HAIC is an investigational triple combination regimen being evaluated for the first-line treatment of advanced or unresectable hepatocellular carcinoma (HCC). The regimen combines anlotinib, an oral multi-targeted tyrosine kinase inhibitor (TKI) that inhibits VEGFR, FGFR, PDGFR, and c-Kit to restrict tumor angiogenesis; benmelstobart (TQB2450), an investigational anti-PD-L1 monoclonal antibody that blocks the PD-1/PD-L1 pathway to restore T-cell-mediated anti-tumor immunity; and hepatic arterial infusion chemotherapy (HAIC), a locoregional treatment delivering the FOLFOX regimen (oxaliplatin, leucovorin, and 5-fluorouracil) directly into the hepatic artery. This combination leverages the synergistic effects of antiangiogenesis, immune checkpoint blockade, and localized high-dose chemotherapy to maximize tumor control and improve survival outcomes in patients with hepatocellular carcinoma.
- Other names
- TQB2450 + anlotinib + HAICanlotinib + TQB2450 + HAICanlotinib combined with benmelstobart and HAICbenmelstobart + anlotinib + HAIC
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)PDGFRB (Platelet-derived growth factor receptor beta)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)RET (Rearranged during transfection receptor tyrosine kinase)FGFR4 (Fibroblast growth factor receptor 4)DNAFGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on anlotinib + benmelstobart + HAIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anlotinib + benmelstobart + HAIC.